This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
AM1 Overzicht aandelen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 1/6 |
| Dividenden | 4/6 |
Beloningen
Risicoanalyse
Amgen Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$288.03 |
| 52 Week Hoogtepunt | US$0 |
| 52 Week Laag | US$0 |
| Bèta | 0.58 |
| 11 maand verandering | 0.84% |
| 3 maanden verandering | -0.54% |
| 1 Jaar Verandering | 20.61% |
| 33 jaar verandering | n/a |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | 4.96% |
Recent nieuws en updates
Recent updates
Rendement voor aandeelhouders
| AM1 | BG Biotechs | BG Markt | |
|---|---|---|---|
| 7D | -8.1% | 0% | 0% |
| 1Y | 20.6% | 0% | 0% |
Rendement versus industrie: AM1 exceeded the BG Biotechs industry which returned -4% over the past year.
Rendement versus markt: AM1 exceeded the BG Market which returned 15.1% over the past year.
Prijsvolatiliteit
| AM1 volatility | |
|---|---|
| AM1 Average Weekly Movement | 3.5% |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in BG Market | 0% |
| 10% least volatile stocks in BG Market | 0% |
Stabiele aandelenkoers: AM1 has not had significant price volatility in the past 3 months.
Volatiliteit in de loop van de tijd: AM1's weekly volatility (3%) has been stable over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1980 | 26,700 | Bob Bradway | www.amgen.com |
Amgen Inc. Samenvatting
| AM1 fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €153.66b |
| Inkomsten(TTM) | €2.86b |
| Inkomsten(TTM) | €28.31b |
53.6x
Koers/Winstverhouding5.4x
P/S-verhoudingIs AM1 overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| AM1 resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$30.93b |
| Kosten van inkomsten | US$11.32b |
| Brutowinst | US$19.62b |
| Overige uitgaven | US$16.49b |
| Inkomsten | US$3.13b |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 5.83 |
| Brutomarge | 63.41% |
| Nettowinstmarge | 10.12% |
| Schuld/Eigen Vermogen Verhouding | 1,057.3% |
Hoe presteerde AM1 op de lange termijn?
Bekijk historische prestaties en vergelijking